title: [Cost-effectiveness of weekly paclitaxel for patients with advanced non-small cell lung cancer].
abstract: Paclitaxel is known to be efficacious in treating non-small cell lung cancer (NSCLC). We initiated a phase II trial of weekly paclitaxel (W-PTX) therapy in advanced NSCLC, and found that W-PTX was feasible for advanced NSCLC patients. We evaluated the cost of W-PTX from receipts and compared it with a standard cisplatin-vinorelbine (VC) regimen. The aim of this study was to assess the cost of W-PTX therapy. Previously untreated patients with stage IV NSCLC and patients with stage III B/IV NSCLC after at least one previous cisplatin based regimen were eligible if they had preserved organ function for treatment. Paclitaxel was administered at a dose of 80 mg/m2 for 3 consecutive weeks on a 4-week cycle. Patients received at least 1 course of W-PTX in our hospital and then, if possible, were treated on outpatients basis. All patients receiving the VC regimen were treated in the hospital. The mean cost of W-PTX for one month was approximately 699,000 yen per inpatient and 236,000 yen per outpatient. On the other hand, the mean cost of VC for one month was approximately 816,000 yen per patient. Although the cost of W-PTX for inpatient did not differ greatly from the cost of VC, the cost of W-PTX for outpatients was significantly lower than that of VC. The findings of this study suggest that W-PTX is feasible as a cost-effective chemotherapy for patients with advanced NSCLC.
authors.affiliation: Third Dept. of Internal Medicine, Faculty of Medicine, Tottori University.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Suyama
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hitsuda
authors.forename: Shingo
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Nakamoto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Shigeoka
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Igishi
authors.forename: Naoto
authors.initials: N
authors.lastname: Burioka
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Yasuda
authors.forename: Takanori
authors.initials: T
authors.lastname: Sako
authors.forename: Masanori
authors.initials: M
authors.lastname: Miyata
authors.forename: Masahiro
authors.initials: M
authors.lastname: Endo
authors.forename: Eiji
authors.initials: E
authors.lastname: Shimizu
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000191:economics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics; D002945:Cisplatin / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000191:economics*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine